NCI-H1437 Xenograft Model Service for NSCLC

The NCI-H1437 xenograft model stands out as the only lung adenocarcinoma platform harboring a documented MAP2K1 Q56P activating mutation, conferring exceptional dependency on MEK1 signaling and marked sensitivity to trametinib and related inhibitors. Alfa Cytology leverages this molecularly distinctive cell line—paired with authenticated banking, optimized implantation protocols, and integrated pharmacodynamic analysis—to advance your preclinical MEK-targeted and combination therapy programs with reproducible, publication-ready data.

Overview of NCI-H1437 Xenograft Model for NSCLC

The NCI-H1437 cell line was established in June 1986 by A.F. Gazdar and J.D. Minna at the National Cancer Institute from pleural effusion metastatic cells of a 60-year-old Caucasian male smoker (70 pack-years) diagnosed with stage 1 lung adenocarcinoma. This line is genetically unique among NSCLC models, carrying a homozygous activating mutation in MAP2K1 (Q56P) that drives constitutive MEK1 kinase activity downstream of RAF, rendering the cells exceptionally dependent on the MAPK/ERK signaling axis. Functional genomics screens using shRNA and CRISPR-Cas9 have confirmed that NCI-H1437 is the sole lung cancer line in large dependency datasets exhibiting this extreme MAP2K1 vulnerability. Additionally, the line harbors a homozygous TP53 mutation (p.Arg267Pro, c.800G>C) and a homozygous deletion of the CDKN2A locus, resulting in loss of p16INK4a-mediated cell cycle checkpoint control and further reinforcing oncogenic proliferation. Both KRAS and EGFR remain wild-type, distinguishing NCI-H1437 from the majority of oncogene-driven NSCLC models and positioning it as an ideal substrate for evaluating MEK1-selective inhibitors and vertical pathway blockade strategies.

Fig 1. Shikonin at 1–2 mg/kg continuously regressed NCI-H1437 xenografts in nude mice, with H1437 tumors maintained at near-constant volume throughout the 15-day treatment course. (Jeung, Yun-Ji, et al., 2016)

In immunodeficient hosts, NCI-H1437 demonstrates reliable tumorigenicity with robust engraftment when 1×10⁷ cells are implanted subcutaneously, typically with Matrigel support to standardize tumor take rates. Tumors become palpable within 7–10 days and progress with consistent kinetics. The model exhibits a non-invasive growth phenotype in three-dimensional matrices, making it particularly suitable for studying primary tumor biology rather than metastatic dissemination. In vivo validation has demonstrated that NCI-H1437 xenografts are profoundly sensitive to the FDA-approved MEK inhibitor trametinib, with treated tumors showing marked growth suppression compared to vehicle controls. These properties render the NCI-H1437 xenograft an indispensable tool for preclinical evaluation of MEK-targeted monotherapy, RAF/MEK/ERK vertical inhibition, and rational combination regimens in a molecularly defined, KRAS/EGFR-wild-type adenocarcinoma context.

Cell Line Information: NCI-H1437

The table below consolidates the essential biological, genetic, and operational characteristics of the NCI-H1437 cell line to support informed experimental design and data interpretation.

Our Services

Alfa Cytology delivers a comprehensive NCI-H1437 xenograft program encompassing authenticated cell banking, mycoplasma and sterility verification, tumor implantation, longitudinal monitoring, and multi-modal endpoint analysis. Our standardized workflows—refined across numerous MAPK-pathway lung cancer studies—ensure consistent engraftment, reproducible tumor growth curves, and pharmacologically meaningful readouts that strengthen your preclinical development decisions.

Workflow of NCI-H1437 Xenograft Model Construction

Construction of the NCI-H1437 xenograft model at Alfa Cytology follows a regimented, IACUC-approved pipeline that prioritizes genetic authenticity, sterile technique, and reproducible tumor growth. Each operational phase is documented under GLP-aligned quality systems to ensure complete auditability from cell thaw to final dataset delivery.

1. Master Cell Bank Revival & Expansion: NCI-H1437 cells are revived from authenticated, low-passage master stocks stored under liquid nitrogen and expanded in RPMI-1640 supplemented with 10% FBS. Each batch undergoes mycoplasma PCR screening, STR profiling confirmation against the published ATCC profile, and viability assessment prior to harvest.
2. Pre-Implantation Cell Preparation: Cultures in logarithmic growth phase are dissociated with trypsin-EDTA, neutralized with complete medium, and pelleted by centrifugation at 200×g for 5 minutes. The pellet is washed twice with sterile PBS to eliminate serum traces, then resuspended in ice-cold PBS at a concentration of 1×10⁸ cells/mL for a final inoculum of 1×10⁷ cells per 100 μL injection volume.
3. Matrigel Mixing & Injection Preparation: High-concentration, phenol-red-free Matrigel is thawed at 4°C overnight and maintained on ice. The cell suspension is mixed 1:1 with cold Matrigel immediately before injection to promote cell retention, angiogenesis, and standardized engraftment kinetics. The mixture is kept on ice at all times to prevent premature polymerization.
4. Subcutaneous Tumor Implantation: Six- to eight-week-old female athymic nude mice are acclimatized for a minimum of seven days. Under aseptic conditions, 200 μL of the cell-Matrigel suspension is injected subcutaneously into the right flank using a 26-gauge needle. Mice are monitored daily for general health and injection-site integrity.
5. Tumor Establishment & Cohort Randomization: Tumors are monitored by palpation beginning on day 5 post-implantation. Once tumors become palpable and reach a mean volume of 80–120 mm³—typically 10–14 days after injection—mice are stratified by tumor size and randomized into vehicle control and treatment cohorts (n = 8–10 per group).
6. Dosing, Monitoring & Endpoint Analysis: Test agents are administered according to protocol-specified routes (PO, IP, IV, or SC) and schedules. Tumor dimensions and body weights are recorded twice weekly; tumor volume is calculated as (width)² × length / 2. Studies conclude at a humane endpoint (typically 2,000 mm³ or 21–28 days post-treatment), at which point tumors are excised, weighed, and allocated for histopathology (H&E), immunohistochemistry (p-ERK, p-MEK, Ki-67, CD31, TUNEL), and molecular profiling (qPCR, Western blot, RNA-seq). Serum is collected for pharmacokinetic correlation where applicable.

Fig 2. NCI-H1437 xenograft model construction workflow.

Case Study

In a recent preclinical evaluation, Alfa Cytology established the NCI-H1437 subcutaneous xenograft to assess the anti-tumor efficacy of a novel MEK1 inhibitor in a MAP2K1-mutant, KRAS-wild-type lung adenocarcinoma context. Following robust tumor engraftment in female athymic nude mice, animals were randomized into vehicle control and treatment arms (n = 8–10 per group) once mean tumor volume reached approximately 100 mm³. The test compound was administered via oral gavage on a daily schedule for 21 days at two escalating dose levels alongside a trametinib reference arm. Longitudinal monitoring revealed dose-dependent tumor growth inhibition in treated animals relative to vehicle controls, with the highest dose cohort demonstrating sustained suppression throughout the treatment window. At study termination, harvested tumors underwent comprehensive histopathological review and biomarker analysis, including p-ERK and p-MEK immunostaining to confirm target engagement, Ki-67 quantification to evaluate proliferative inhibition, and TUNEL assay to assess apoptotic induction. Body weight records remained stable across all cohorts, indicating an acceptable tolerability profile. Complete pharmacodynamic datasets, including individual tumor growth trajectories and immunohistochemistry images, are available for disclosure under a confidentiality agreement.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H1437 xenograft program provides access to a purpose-built infrastructure optimized for MAPK-pathway lung cancer preclinical research. Our service architecture combines scientific depth with operational agility to accelerate your compound evaluation timeline.

• Authenticated NCI-H1437 master and working cell banks are maintained under liquid nitrogen with biannual STR confirmation against the ATCC reference profile and documented mycoplasma negativity, ensuring genetic stability across every study.
• Standardized implantation protocols with Matrigel support yield consistent tumor engraftment and predictable growth kinetics in this non-invasive adenocarcinoma model, enabling precise power calculations and efficient cohort sizing.
• Flexible study architectures accommodate single-agent MEK inhibitor, RAF/MEK/ERK vertical blockade, combination, and dose-escalation designs, with dosing routes and schedules tailored to your compound properties.
• On-site histopathology and IHC capabilities—including p-ERK, p-MEK, Ki-67, CD31, and TUNEL—deliver rapid turnaround without external vendor coordination or sample custody interruptions.
• Secure client data portals provide real-time visibility into tumor measurements, body weights, and study milestones, with automated notifications at predefined protocol checkpoints.
• Each engagement is supported by a dedicated scientific project manager who coordinates weekly progress reports, interim data presentations, and adaptive protocol amendments aligned with your evolving research priorities.

Contact Us

If your research pipeline targets the MAPK pathway—whether advancing a next-generation MEK1 inhibitor, exploring RAF/MEK/ERK vertical blockade, or investigating chemosensitization strategies in a KRAS-wild-type adenocarcinoma context—Alfa Cytology offers the NCI-H1437 xenograft expertise to advance your preclinical objectives with scientific rigor. Reach out to our scientific team today to discuss your study parameters, request a customized proposal, or arrange a consultation with our oncology model specialists. We are committed to converting your therapeutic hypothesis into robust, publication-ready preclinical evidence.

For research use only. Not intended for any clinical use.